Loading…
CNS biotech selling Auvelity for depression and developing/marketing other neuroscience drugs for narcolepsy and migraine.
CNS biotech selling Auvelity for depression and developing/marketing other neuroscience drugs for narcolepsy and migraine.
Sells prescription drugs in the US through its own sales team, with Auvelity leading sales and Sunosi bought from Jazz Pharmaceuticals in 2022. Prescription growth and insurer coverage, rather than price, drive revenue, and further sales depend on getting approval for additional uses of its existing drugs.
Moat: narrow (IP / patents, regulatory licence). A novel NMDA-receptor mechanism (Auvelity) is patent-protected and differentiated from standard antidepressants.
Headquarters: New York, New York, US · Founded: 2012 · Employees: 925
Size Axsome Therapeutics (AXSM) is a United States Health Care company (Biotechnology) with a market value of $6.96B, the 964th largest of 3,117 United States companies the cockpit tracks. Shares closed at $132.37 on 6 Nov 2026.
Performance Over six months the shares fell 39.1%, against +2.4% for the median peer and -1.1% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 54.2% over the last twelve months (peer median +18.0%); the operating margin is -18.9% (peer median -2.3%).
Valuation It trades at 75.5× forward earnings against a peer median of 69.9× (3rd most expensive of 8).
Short interest Short interest is 5.9% of the free float (15 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $865M | $638M | $386M | $271M | $50.0M |
| Revenue growth | — | +66% | +43% | +441% | — |
| Gross profit | $796M | $582M | $344M | $238M | $39.3M |
| EBITDA | -$153M | -$160M | -$244M | -$176M | -$170M |
| Net income | -$157M | -$183M | -$287M | -$239M | -$187M |
| Free cash flow | -$82.6M | -$93.9M | -$129M | -$146M | -$117M |
| Capital expenditure | $839,000 | $480,000 | $270,000 | $582,000 | $702,109 |
| Total debt | $224M | $218M | $203M | $186M | $94.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Axsome Therapeutics AXSM | $6.96B | -39% | +54% | -19% | 75.5× | n/a |
| Johnson & Johnson JNJ | $665B | +26% | +8% | 26% | 24.5× | 3.5% |
| Otsuka Hldgs 4578.T | $38.6B | +2% | +11% | 18% | 16.3× | 0.4% |
| Jazz Pharmaceuticals Public JAZZ | $15.1B | +4% | +13% | 25% | 8.9× | -3.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AXSM | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -22.2% | -1.2% | 3rd lowest of 21 |
| 6-month return | -39.1% | +2.4% | lowest of 21 |
| Distance from 52-week high | -49.1% | -29.4% | 2nd lowest of 21 |
| Revenue growth (TTM) | +54.2% | +18.0% | 4th highest of 15 |
| Operating margin | -18.9% | -2.3% | 7th lowest of 15 |
| Forward P/E | 75.5× | 69.9× | 3rd most expensive of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Axsome Therapeutics AXSM | United States | $6.96B | -39% | +54% | -19% | 75.5× | n/a | n/a |
| Caris Life Sciences CAI | United States | $7.13B | +56% | +85% | 15% | 86.1× | 18.7% | +85.4% |
| CG Oncology CGON | United States | $6.74B | +9% | +1,030% | -4,056% | n/a | n/a | n/a |
| Immunovant IMVT | United States | $6.31B | +5% | n/a | n/a | n/a | n/a | n/a |
| 10x Genomics TXG | United States | $7.72B | +174% | -4% | -14% | n/a | 41.8% | +16.6% |
| Kodiak Sciences KOD | United States | $6.24B | +142% | n/a | n/a | n/a | n/a | n/a |
| Twist Bioscience TWST | United States | $7.95B | +112% | +19% | -32% | n/a | n/a | n/a |
| Arrowhead Pharmaceuticals ARWR | United States | $8.22B | -20% | +17% | -34% | n/a | n/a | n/a |
| Scholar Rock SRRK | United States | $5.72B | -3% | n/a | n/a | n/a | n/a | n/a |
| Hangzhou Tigermed Consulting 3347.HK | Hong Kong | $5.65B | -1% | +22% | 10% | 71.8× | 28.3% | +15.6% |
| Genscript Biotech 1548.HK | Hong Kong | $8.81B | +96% | +53% | 12% | 297.9× | 36.5% | +19.8% |
| Cogent Biosciences COGT | United States | $5.49B | -9% | n/a | n/a | n/a | n/a | n/a |
| Anthem Biosciences ANTHEM.NS | India | $5.46B | +17% | -1% | 35% | 69.9× | 36.7% | +26.2% |
| Krystal Biotech KRYS | United States | $8.92B | -2% | +26% | 48% | 34.7× | 11.9% | +26.0% |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.35B | -2% | -28% | -210% | n/a | -6.4% | -10.0% |
| 3SBio 1530.HK | Hong Kong | $4.92B | -34% | +102% | 61% | 13.7× | n/a | n/a |
| Edgewise Therapeutics EWTX | United States | $4.89B | +28% | n/a | n/a | n/a | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.89B | -11% | -22% | 17% | 13.7× | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $4.86B | -9% | -34% | -2,059% | n/a | n/a | n/a |
| Vaxcyte PCVX | United States | $10.1B | +21% | n/a | n/a | n/a | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.81B | -1% | -61% | -11,441% | n/a | n/a | n/a |